Abstract
Background T2-weighted MRI is standard for detecting clinically significant prostate cancer (csPCa) by identifying visible lesions that stand out from the background prostate.
Purpose To determine whether patients with csPCa have abnormal T2-weighted signal in non-lesion, background prostate tissue (BP).
Methods This retrospective study included two patient cohorts who underwent 3T MRI examination for suspected csPCa. Median (urine-normalized) T2-weighted signal was computed for BP and compared between patients with and without csPCa. csPCa discrimination performance of T2-weighted BP signal was evaluated using area under receiver operating characteristic curves (AUC). T2 and S0 (a proxy for proton density) were computed and compared between patients with and without csPCa. T2 was also recomputed using larger buffers around csPCa lesions. csPCa discrimination performance was compared between two predictors: Restriction Spectrum Imaging (RSI) C1 and RSI C1 normalized by global prostate median T2-weighted signal.
Results Cohort 1: 46 patients (age: 64±10 years). Cohort 2: 151 patients (65±8 years). Urine-normalized T2-weighted signal was systematically lower in BP of subjects with csPCa (p≤0.034) and indicated the presence of cancer (cohort 1: AUC=0.80; cohort 2: AUC=0.68). BP T2 was significantly lower in csPCa patients (p≤0.011), while S0 was not (p≥0.30). BP T2 measurements were stable to within 5% with buffers from 0 to 30 mm around visible lesions. csPCa discrimination improved with incorporation of BP T2-weighted signal (cohort 1: AUC=0.72 for RSI C1 alone, versus 0.81 with BP T2-weighted signal; cohort 2: AUC=0.63 versus 0.76).
Conclusion Lower T2-weighted signal in BP suggests the presence of csPCa.
Competing Interest Statement
AMD is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. and receives funding through research agreements with General Electric Healthcare. RRP is a consultant for Human Longevity, Inc. She also receives funding through research grants from GE Healthcare and Imagine Scientific to the University of California San Diego; she has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. She also has equity interest in CureMetrix. TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of the above arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Funding Statement
This work was funded by the Prostate Cancer Foundation, the American Society for Radiation Oncology, and the National Institutes of Health (#K08EB026503, #UL1TR000100)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of University of California San Diego gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Support: This work was supported, in part, by the Prostate Cancer Foundation, the American Society for Radiation Oncology, and the National Institutes of Health (#K08EB026503, #UL1TR000100)
Conflict of Interest Disclosure: AMD is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory Board of Human Longevity, Inc. and receives funding through research agreements with General Electric Healthcare. RRP is a consultant for Human Longevity, Inc. She also receives funding through research grants from GE Healthcare and Imagine Scientific to the University of California San Diego; she has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. She also has equity interest in CureMetrix. TMS reports honoraria from Multimodal Imaging Services Corporation, Varian Medical Systems, and WebMD; he has an equity interest in CorTechs Labs, Inc. and serves on its Scientific Advisory Board. These companies might potentially benefit from the research results. The terms of the above arrangements have been reviewed and approved by the University of California San Diego in accordance with its conflict-of-interest policies.
Translational Relevance: Diagnosis of prostate cancer has been considerably improved by the introduction of MRI. Research on this topic has focused on detecting and characterizing MRI-visible lesions, identified by comparing the lesions to the background prostate tissue. In this study, we demonstrate that the background, non-lesion prostate tissue is also abnormal on MRI in patients with cancer. This finding suggests that the MRI signal of background prostate tissue affords complementary diagnostic information to lesion-specific analysis that could improve clinical decision-making around biopsy. It also shows that MRI can inform the investigation of biological changes beyond identified index lesion(s). Whether the observed abnormalities in background prostate tissue reflect tumor-induced effects, a field effect predisposing to high-grade cancer, or some combination of both, they motivate a new line of inquiry for rad-path correlation in prostate cancer.
Additional analyses included for results shown in figures 3 and 5. Table 1 updated with additional information.
Data Availability
All data produced in the present study are available upon reasonable request to the corresponding author
